Quiz

PsA, PsO, and PEST

Priyam Vora, Associate Editor

06/16/2023

© 2023 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Rheumatology and Arthritis Learning Network or HMP Global, their employees, and affiliates.

Popular Articles

News

Ultraprocessed Food Intake and SLE Incidence Among Women

07/12/2024

Jessica Garlewicz

Sugar- and artificially sweetened-beverages were among the key contributors to heightened risk of developing systemic lupus erythematosus.

Sugar- and artificially sweetened-beverages were among the key contributors to heightened risk of developing systemic lupus erythematosus.

Sugar- and artificially...

07/12/2024

Rheumatology & Arthritis

News

Subcutaneous Ustekinumab Cost Rose 84% Under Medicare Part D, Set to Drop Under Negotiated Price Reduction

08/15/2024

Rebecca Mashaw

Coverage changes omitted self-injected therapies from Part B, but new negotiated price will reduce costs 66-67%.

Coverage changes omitted self-injected therapies from Part B, but new negotiated price will reduce costs 66-67%.

Coverage changes omitted...

08/15/2024

Rheumatology & Arthritis

Sponsored Video

The RheuMuseum Lecture Series: The Pathogenesis of Psoriatic Arthritis

06/04/2024

The RheuMuseum Lecture Series continues with Professor Iain McInnes taking a deeper dive into the pathogenesis of psoriatic arthritis.

The RheuMuseum Lecture Series continues with Professor Iain McInnes taking a deeper dive into the pathogenesis of psoriatic arthritis.

The RheuMuseum Lecture Series...

06/04/2024

Rheumatology & Arthritis

FDA Alert

FDA Approves Bimekizumab for PsA, nr-axSpA and AS

09/23/2024

Rebecca Mashaw

Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Already approved for plaque...

09/23/2024

Rheumatology & Arthritis

News

Predictors of Demyelinating Disease in axSpA

07/11/2024

Jessica Garlewicz

Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.

Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.

Key predictors of demyelinating...

07/11/2024

Rheumatology & Arthritis

Partner Spotlight

Axial Involvement in SpA: A Patient-Centered Exploration, Chapter 1

SPONSORED

Axial Involvement in SpA, Chapter 1

04/26/2022

Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.

Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.

Ethan Craig, MD, MPH, discusses...

04/26/2022

Rheumatology & Arthritis